Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
C 319.39 -0.19% -0.61
BGNE closed down 0.19 percent on Monday, March 1, 2021, on approximately normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Down
Historical BGNE trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
50 DMA Support Bullish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Inside Day Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -0.19%
Stochastic Reached Oversold Weakness -4.63%
Oversold Stochastic Weakness -4.63%
50 DMA Support Bullish -3.93%
Older End-of-Day Signals for BGNE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Support about 11 hours ago
2x Volume Pace about 11 hours ago
1.5x Volume Pace about 11 hours ago
Down 1% about 11 hours ago
Up 2% about 11 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


BeiGene, Ltd. Description

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancers Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Kras Humanized Antibody Ras Subfamily Braf Bruton's Tyrosine Kinase Rp1

Is BGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 388.97
52 Week Low 118.55
Average Volume 325,107
200-Day Moving Average 257.41
50-Day Moving Average 318.81
20-Day Moving Average 353.87
10-Day Moving Average 339.56
Average True Range 16.60
ADX 25.5
+DI 19.69
-DI 32.94
Chandelier Exit (Long, 3 ATRs ) 339.16
Chandelier Exit (Short, 3 ATRs ) 360.51
Upper Bollinger Band 395.09
Lower Bollinger Band 312.65
Percent B (%b) 0.08
BandWidth 23.30
MACD Line -0.62
MACD Signal Line 7.30
MACD Histogram -7.9223
Fundamentals Value
Market Cap 29.04 Billion
Num Shares 90.9 Million
EPS -11.29
Price-to-Earnings (P/E) Ratio -28.30
Price-to-Sales 63.24
Price-to-Book 4.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 337.35
Resistance 3 (R3) 337.88 332.42 334.35
Resistance 2 (R2) 332.42 327.85 332.16 333.35
Resistance 1 (R1) 325.91 325.03 329.17 325.38 332.36
Pivot Point 320.45 320.45 322.08 320.19 320.45
Support 1 (S1) 313.94 315.88 317.20 313.41 306.42
Support 2 (S2) 308.48 313.06 308.22 305.43
Support 3 (S3) 301.97 308.48 304.43
Support 4 (S4) 301.44